CATALAYER NEWS
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Conducted in China – Company Announcement - - Financial Times
Source: Financial Times · 2026-09-13
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Conducted in China – Company Announcement - Financial Times
MORE FROM FINANCIAL TIMES
The calculated desperation of Trump-a-palooza - Financial Times
2026-09-13
Russia hits evacuated Kyiv-Warsaw train on line used by foreign leaders - Financial Times
2026-09-13
Will the Fed defy Trump and raise rates? - Financial Times
2026-09-13
Will the Fed defy Trump and raise rates? - Financial Times
2026-09-13
Why teenagers are doing worse at school - Financial Times
2026-09-13
RELATED ON CATALAYER
Related Topics
China Trade & Tech Policy NewsRELATED MARKETS
Prediction Markets